In vitro effect of amantadine and interferon α-2a on hepatitis C virus markers in cultured peripheral blood mononuclear cells from hepatitis C virus-infected patients

Martín, José Manuel García; Navas, Sonia; Fernández, María Beatriz Carenas; Rico, Miguel A.; Pardo, Margarita; Quiroga, Juan Antonio; Zahm, Friederike; Carréño, Vicente

doi:10.1016/s0166-3542(99)00017-0

Cited by 34 publications

(29 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interferon monotherapy has yielded low sustained response rates, and other effective drug combinations are unknown [12]. Amantadine has been proposed as a possible alternative to ribavirin based on experimental data and preliminary clinical trials in HIV-seronegative patients [13][14][15][16].…”

Section: Introductionmentioning

confidence: 99%

Pilot Study of Interferon-α with and without Amantadine for the Treatment of Hepatitis C in HIV Co-infected Individuals on Antiretroviral Therapy

Sax

Friedl²,

Renner

et al. 2001

Infection

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Pilot Study of Interferon-α with and without Amantadine for the Treatment of Hepatitis C in HIV Co-infected Individuals on Antiretroviral Therapy

Sax

Friedl²,

Renner

et al. 2001

Infection

View full text Add to dashboard Cite

show abstract

“…In vitro, amantadine alone (2 microM) suppressed peripheral blood mononuclear cells proliferative response induced by both HCV core and NS3-specific antigens (Martin et al, 1999). Its antiproliferative effect was greater than that of IFN alpha.…”

Section: Discussionmentioning

confidence: 94%

Amantadine therapy in renal transplant patients with hepatitis C virus infection

Kamar

Rostaing

Sandres-Sauné³

et al. 2004

Journal of Clinical Virology

View full text Add to dashboard Cite

“…Recent reports indicate that amantadine combination therapy with IFN [24] and with IFN and ribavirin [25] may increase the biochemical and virological response. This new therapeutic approach to chronic hepatitis C could play a role in the treatment of elderly patients, but only after careful individual evaluation.…”

Section: Discussionmentioning

confidence: 99%

Antiviral Activity of Amantadine in Elderly Patients with Chronic Hepatitis C

et al. 2001

View full text Add to dashboard Cite

Background: Hepatitis C virus (HCV) infection is a worldwide problem of public health. Epidemiological studies have shown a significant higher prevalence of infection in the elderly. Amantadine is an antiviral agent active against the influenza A virus that has been used in cases of chronic hepatitis C. Objectives: To evaluate the antiviral activity and the safety of amantadine (200 mg daily for 6 months) in elderly patients with chronic hepatitis C. Methods: The study group consisted of 23 consecutive patients over 65 years suffering from chronic hepatitis C. Aminotransferase (ALT) levels were tested at baseline, at 15 days and then monthly until the end of therapy. HCV genotype was determined at baseline. A quantitative HCV-RNA measurement was performed at baseline, at 15 days and at the 1st, 3rd and 6th month of treatment. Results: 13 males and 10 females were enrolled (mean age 70.1 ± 3.4 years; range: 65–75). The mean ALT levels did not change significantly during therapy except in 1 patient subsequently returned normal. The HCV-RNA remained detectable in all patients, but a significant difference in response was observed in patients infected by genotype 1b. Conclusions: Our results confirm the antiviral activity of amantadine against HCV, mainly for genotype 1b with initial high viral load. No consistent effects on aminotransferases were observed.

show abstract

In vitro effect of amantadine and interferon α-2a on hepatitis C virus markers in cultured peripheral blood mononuclear cells from hepatitis C virus-infected patients

Cited by 34 publications

References 60 publications

Pilot Study of Interferon-α with and without Amantadine for the Treatment of Hepatitis C in HIV Co-infected Individuals on Antiretroviral Therapy

Pilot Study of Interferon-α with and without Amantadine for the Treatment of Hepatitis C in HIV Co-infected Individuals on Antiretroviral Therapy

Amantadine therapy in renal transplant patients with hepatitis C virus infection

Antiviral Activity of Amantadine in Elderly Patients with Chronic Hepatitis C

Contact Info

Product

Resources

About